HGMI HEALTH

Including 6-8 Japanese nationals in phase 1 studies will dramatically increase the VALUE of the data of your drug, as it will add the third largest market in the world... When you initiate a Global Phase 3 study in Japan, prior PK data and/or Safety data with Japanese subjects will be required. Phase 1/PK studies including Japanese cohort are effective in the speedy clinical development... A large number of experiences of clinical studies in the US and Japan (As both a sponsor and CRO) Multiple relationships with reliable CROs, clinical sites, hospitals and consultants in the US and Japan

Also known as: HGMI Health, Co. Inc.

Primary location: New York United States